Showing results (51-60 of 66) with videos related to
Sort By:
Pageof 7
The Lancet. Oncology|March 9, 2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLesley Seymour, Jan Bogaerts, Andrea Perrone, et al.European Journal of Cancer (Oxford, England : 1990)|May 31, 2016
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupLawrence H Schwartz, Lesley Seymour, Saskia Litière, et al.Communications Biology|July 29, 2020
Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trialLaurent Jacob, Anke Witteveen, Inès Beumer, et al.European Journal of Cancer (Oxford, England : 1990)|April 8, 2023
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of CancerRobbe Saesen, Mieke Van Hemelrijck, Jan Bogaerts, et al.European Journal of Cancer (Oxford, England : 1990)|May 19, 2016
RECIST 1.1-Update and clarification: From the RECIST committeeLawrence H Schwartz, Saskia Litière, Elisabeth de Vries, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041)Hanneke W M van Laarhoven, Walter Fiedler, Ingrid M E Desar, et al.European Journal of Cancer (Oxford, England : 1990)|May 8, 2019
Addressing the dichotomy between individual and societal approaches to personalised medicine in oncologyRoberto Salgado, David B Solit, David L Rimm, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit ScoreNathan I Cherny, Elisabeth G E de Vries, Urania Dafni, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working GroupAlexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III TrialSuzette Delaloge, Martine Piccart, Emiel Rutgers, et al.Pageof 7